Not provided
Not provided
Not provided
Not provided
Not provided
COVID-19 Pandemic
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mount Sinai Rehabilitation Hospital | OTHER |
| City University of New York, School of Public Health | OTHER |
Not provided
Not provided
Not provided
Not provided
This study will compare the effectiveness of a traditional, continuous walking rehabilitation program for people with MS to the novel intervention of an intermittent or interval walking rehabilitation program. Half of the participants will receive the continuous walking program while the other half will receive the novel intermittent walking program.
The typical rehabilitation of walking difficulties for people with MS has included practice walking. In general, this includes training to build walking endurance by having the person with MS walk until he/she becomes tired and needs to stop. Although this model has been used successfully to treat people with other diagnoses, it has limited effectiveness in improving walking ability and endurance in people with MS because of fatigue. Recently, a different model has been considered: intermittent or interval walking training. Interval walking training is organized such that seated rest breaks are intentionally interspersed between walking training bouts that end before the person with MS becomes too tired to continue. Exploratory research has shown that people with MS can walk faster and farther when using interval walking training, and may have more improvements in walking ability and endurance after using interval walking training. This study will compare the effectiveness of the traditional model of continuous walking training to the promising new model of interval walking training. This will help to determine whether interval or continuous walking training is superior in improving walking ability and endurance in people with MS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous Walking | Active Comparator | Participants in the Continuous Walking (CONT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the CONT group will be to complete a 6-minute long walk without rest breaks |
|
| Interval Walking | Experimental | Participants in the Interval Walking (INT) arm will undergo training 2x/week for 6 weeks for a total plan of 12 training sessions. The intervention for the (INT) group will be to complete three 2-minute-long walks with 2-minute seated rest breaks between each walk |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Walking | Other | Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in 6-minute Walk Test distance | Is a measurement of the distance (in meters) walked at best pace in six minutes. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in 12-item Multiple Sclerosis Walking Scale score | A survey that measures a participant's perception of how his/her walking ability is affected by multiple sclerosis. The scale ranges from 0-100 with lower scores representing a lesser impact of multiple sclerosis on the participant's walking ability. There are no subscales. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Evan T Cohen, PhD | Rutgers, The State University of New Jersey | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mandell Center for Multiple Sclerosis - Mount Sinai Rehabilitation Hospital | Hartford | Connecticut | 06112 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016138 | Walking |
| ID | Term |
|---|---|
| D008124 | Locomotion |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Randomized controlled pre-post study
Not provided
Not provided
Assessors blinded to experimental condition
| Change in Fatigue Severity Scale score | A survey that measures a participant's perception of the impact of the symptom of fatigue on a person's ability to participate in life roles. The scale ranges from from 9-63, with lower scores representing a lower impact of fatigue on the ability to perform the activities listed in the scale.There are no subscales. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| Change in Step Length | The distance (in centimeters) traversed in one step from initial contact of one foot to the initial contact of the opposite foot. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| Change in Step Time | The time (in seconds) taken to complete one step from initial contact of one foot to the initial contact of the opposite foot. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| Change in Stride Velocity | The speed with which it takes a person to complete one stride from initial contact of one foot to the next initial contact of the same foot | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| Change in Cadence | The number of steps (the initial contact of one foot to the initial contact of the opposite foot taken per minute | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D015444 | Exercise |
| D009043 | Motor Activity |